| Metastasis from malignant neoplasm of colon and/or rectum
Cyramza vs Erbitux
Side-by-side clinical, coverage, and cost comparison for metastasis from malignant neoplasm of colon and/or rectum.Deep comparison between: Cyramza vs Erbitux with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsErbitux has a higher rate of injection site reactions vs Cyramza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Erbitux but not Cyramza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cyramza
Erbitux
At A Glance
IV infusion
Every 2 weeks
VEGFR2 antagonist
IV infusion
Weekly or every 2 weeks
EGFR antagonist
Indications
- Gastric Adenocarcinoma
- Non-Small Cell Lung Carcinoma
- Metastasis from malignant neoplasm of colon and/or rectum
- Liver carcinoma
- Squamous cell carcinoma of the head and neck
- Metastasis from malignant neoplasm of colon and/or rectum
Dosing
Gastric Adenocarcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent or in combination with weekly paclitaxel.
Non-Small Cell Lung Carcinoma (EGFR exon 19/21, first-line) 10 mg/kg every 2 weeks by IV infusion in combination with erlotinib.
Non-Small Cell Lung Carcinoma (post-platinum progression) 10 mg/kg by IV infusion on Day 1 of a 21-day cycle in combination with docetaxel.
Metastasis from malignant neoplasm of colon and/or rectum 8 mg/kg every 2 weeks by IV infusion prior to FOLFIRI.
Liver carcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent.
Squamous cell carcinoma of the head and neck In combination with radiation therapy: initial 400 mg/m2 IV (120-min) one week prior to radiation, then 250 mg/m2 weekly (60-min) for 6-7 weeks, completing infusion 1 hour prior to radiation; as single-agent or with platinum-based therapy and fluorouracil: weekly (400 mg/m2 initial, 250 mg/m2 subsequent) or biweekly (500 mg/m2 every 2 weeks), completing infusion 1 hour prior to chemotherapy.
Metastasis from malignant neoplasm of colon and/or rectum As single-agent or in combination with irinotecan or FOLFIRI: weekly (400 mg/m2 initial, 250 mg/m2 subsequent) or biweekly (500 mg/m2 every 2 weeks), completing infusion 1 hour prior to irinotecan or FOLFIRI; in combination with encorafenib (BRAF V600E mutation-positive): initial 400 mg/m2 IV (120-min), then 250 mg/m2 weekly (60-min).
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Hypertension, fatigue/asthenia, neutropenia, diarrhea, epistaxis, peripheral edema, stomatitis, proteinuria, thrombocytopenia, decreased appetite, nausea.
Serious Febrile neutropenia, pneumonia, hemorrhage, gastrointestinal perforation, arterial thromboembolic events, impaired wound healing, posterior reversible encephalopathy syndrome, proteinuria including nephrotic syndrome, infusion-related reactions, sepsis.
Postmarketing Thrombotic microangiopathy, hemangioma, dysphonia, arterial aneurysms/dissections/rupture, heart failure.
Most common (>=25%) Cutaneous adverse reactions (rash, pruritus, nail changes), headache, diarrhea, infection; with encorafenib: fatigue, nausea, diarrhea, dermatitis acneiform, abdominal pain, decreased appetite, arthralgia, rash.
Serious Infusion reactions, cardiopulmonary arrest, pulmonary toxicity, dermatologic toxicity (acneiform rash), hypomagnesemia and electrolyte abnormalities, pulmonary embolism.
Postmarketing Aseptic meningitis, mucosal inflammation, Stevens-Johnson syndrome, toxic epidermal necrolysis, life-threatening and fatal bullous mucocutaneous disease.
Pharmacology
Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands VEGF-A, VEGF-C, and VEGF-D, inhibiting ligand-stimulated activation of VEGFR2 and thereby inhibiting endothelial cell proliferation, migration, and angiogenesis.
EGFR antagonist; cetuximab is a recombinant human/mouse chimeric IgG1 monoclonal antibody that binds specifically to the extracellular domain of EGFR, competitively inhibiting EGF and other ligand binding, blocking receptor-associated kinase phosphorylation, inhibiting cell growth, inducing apoptosis, decreasing matrix metalloproteinase and VEGF production, and mediating antibody-dependent cellular cytotoxicity (ADCC) against certain human tumor types.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cyramza
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Erbitux
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Cyramza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Erbitux
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (3/8) · Qty limit (0/8)
Humana
Cyramza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Erbitux
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cyramza.
Cost estimate not availableAssistance Fund: Head and Neck Cancer: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CyramzaView full Cyramza profile
ErbituxView full Erbitux profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.